Pharmabiz

Foresee Pharma gets fourth positive recommendation from DSMB to continue the Casppian Ph3 study, for central precocious puberty

Foresee Pharma gets fourth positive recommendation from DSMB to continue the Casppian Ph3 study, for central precocious puberty: Taipei Friday, February 6, 2026, 18:00 Hrs [IST] F ...
Business Insider

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event ...
Nasdaq

DSMB Recommends Continuation Of SeaStar Medical's NEUTRALIZE-AKI Trial, Sample Size Increased

(RTTNews) - SeaStar Medical Holding Corporation (ICU), a commercial-stage healthcare company, yesterday announced that the independent Data Safety Monitoring Review Board (DSMB) has recommended the ...
Nasdaq

Creative Medical advances FDA cleared ADAPT trial with independent review

Creative Medical Technology (CELZ) announces the successful completion of an independent interim safety review by the Data Safety Monitoring Board, DSMB, for its ADAPT clinical trial. The trial ...
Seeking Alpha

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the ...
Business Insider

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Vancouver, Canada, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and ...

Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces the fourth positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The ...